A randomized, controlled trial of the toxin-blocking effects of B subunit in family members of patients with cholera.
A randomized, controlled field trial was performed to test the ability of B subunit, the nontoxic, binding portion of cholera toxin, to block the toxin receptors (GM1 ganglioside) in the small intestine and thereby prevent diarrhea in individuals infected with Vibrio cholerae O1. Of 1,922 family contacts of 370 index patients selected randomly to receive orally on two successive days either B subunit (low dose, 1.0 mg; high dose, 5.0 mg) or placebo, 190 were asymptomatically infected on day 1 or day 2 of the study and within 24 hr of receiving B subunit. During the first 24-hr period of follow-up, the relative risk of disease among contacts receiving B subunit versus placebo was 0.18 for the low dose (P = .08) and 0.50 for the high dose (P = .22). Subsequently the relative risk increased toward 1.0 and was at no single point significantly reduced, although in five of the six follow-up periods the risk of disease was less in the B subunit group.
D000992:Antitoxins / Q000032:analysis; D002771:Cholera / Q000235:genetics / Q000276:immunology / Q000517:prevention & control*; D002772:Cholera Toxin / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003967:Diarrhea / Q000517:prevention & control*; D004768:Enterotoxins / Q000276:immunology; D005260:Female; D006801:Humans; D008297:Male; D011897:Random Allocation
D000992:Antitoxins; D004768:Enterotoxins; C037420:stN protein, Vibrio cholerae; D002772:Cholera Toxin